NORDSON CORP
For the period ended Apr 30, 2026. Filed May 21, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Apr 30, 2026 · Filed May 21, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Notes to Condensed Consolidated Financial Statements
April 30, 2026
NOTE REGARDING AMOUNTS AND FISCAL YEAR REFERENCES
In this Quarterly Report on Form 10-Q, all amounts related to U.S. dollars and foreign currency and to the number of Nordson Corporation’s common shares, except for per share earnings and dividend amounts, are expressed in thousands. Unless the context otherwise indicates, all references to “we” or the “Company” mean Nordson Corporation.
Unless otherwise noted, all references to years relate to our fiscal year ending October 31.
Significant accounting policies
Basis of presentation. The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles in the United States ("U.S. GAAP") for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six months ended April 30, 2026 are not necessarily indicative of the results that may be expected for the full year. For further information, refer to the Consolidated Financial Statements and notes included in our Annual Report on Form 10-K for the year ended October 31, 2025.
Consolidation. The Condensed Consolidated Financial Statements include the accounts of Nordson Corporation and its 100%-owned and controlled subsidiaries. Investments in affiliates and joint ventures in which our ownership is 50% or less or in which we do not have control but have the ability to exercise significant influence are accounted for under the equity method. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of estimates. The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements. Actual amounts could differ from these estimates.
Revenue recognition. A contract exists when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of the consideration is probable. Revenue is recognized when performance obligations under the terms of the contract with a customer are satisfied. Generally, our revenue results from short-term, fixed-price contracts and primarily is recognized as of a point in time when the product is shipped or at a later point when the control of the product transfers to the customer. For products in which control transfers upon delivery, revenue is deferred for undelivered items and included within Accrued liabilities in our Consolidated Balance Sheets. Revenues deferred as of April 30, 2026 and October 31, 2025 were not material.
For certain contracts related to the sale of customer-specific products, revenue is recognized over time as we satisfy performance obligations because of the continuous transfer of control to the customer. The continuous transfer of control to the customer occurs as we enhance assets that are customer controlled, and we are contractually entitled to payment for work performed to date plus a reasonable margin.
As control transfers over time for these products or services, revenue is recognized based on progress toward completion of the performance obligations. The selection method to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided. We have elected to use the input method – costs incurred for these contracts because it best depicts the transfer of products or services to the customer based on incurring costs on the contract. Under this method, revenues are recorded proportionally as costs are incurred. Contract assets recognized are recorded in Prepaid expenses and other current assets and contract liabilities are recorded in Accrued liabilities in our Consolidated Balance Sheets and were not material as of April 30, 2026 and October 31, 2025. Revenue recognized over time represented approximately less than ten percent of our overall consolidated revenues for the periods ended April 30, 2026 and October 31, 2025.
Revenue is measured as the amount of consideration we expect to be entitled to in exchange for transferring products or services. Taxes, including sales and value add, that we collect concurrently with revenue-producing activities are excluded from revenue. As a practical expedient, we may exclude the assessment of whether goods or services are performance obligations, if they are immaterial in the context of the contract, and combine these with other performance obligations. While payment terms and conditions vary by contract type, we have determined that our contracts generally do not include a significant financing component. We have elected to apply the practical expedient to treat all shipping and handling costs as fulfillment costs, as a significant portion of these costs are incurred prior to transfer of control to the customer. We have also elected to apply the practical expedient to expense sales commissions as they are incurred, as the amortization period resulting from capitalizing the costs is one year or less. These costs are recorded within Selling and administrative expenses in our Condensed Consolidated Statements of Income.
We offer assurance-type warranties on our products as well as separately sold warranty contracts. Revenue related to warranty contracts that are sold separately is recognized over the life of the warranty term and is not material. Certain arrangements may include installation, installation supervision, training, and spare parts, which tend to be completed in a short period of time, at an insignificant cost, and utilizing skills not unique to us, and therefore, these items are typically regarded as inconsequential or not material.
We disclose disaggregated revenues by operating segment and geography in accordance with the revenue standard and on the same basis used internally by the chief operating decision maker for evaluating performance of operating segments and for allocating resources. Refer to our Operating segments Note for details.
Earnings per share. Basic earnings per share are computed based on the weighted-average number of common shares outstanding during each year, while diluted earnings per share are based on the weighted-average number of common shares and common share equivalents outstanding. Common share equivalents consist of shares issuable upon exercise of stock options computed using the treasury stock method, as well as restricted shares and deferred stock-based compensation. Options whose exercise price is higher than the average market price are excluded from the calculation of diluted earnings per share because the effect would beanti-dilutive. Options for 0 and 336 common shares were excluded from the calculation of diluted earnings per share for the three months ended April 30, 2026 and 2025, respectively, because their effect would have been anti-dilutive. Options for 37 and 264 common shares were excluded from the calculation of diluted earnings per share for the six months ended April 30, 2026 and 2025, respectively, because their effect would have been anti-dilutive. Under the 2021 Stock Incentive and Award Plan, executive officers and selected other key employees receive common share awards based on corporate performance measures over three-year performance periods. Awards for which performance measures have not been met were excluded from the calculation of diluted earnings per share.
Recently issued accounting standards
In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 requires enhanced disclosures about significant segment expenses and enhanced disclosures in interim periods. The guidance in ASU 2023-07 is to be applied retrospectively and is effective for annual reporting periods in fiscal years beginning after December 15, 2023 and interim reporting periods in fiscal years beginning after December 31, 2024, with early adoption permitted. The Company adopted the guidance of ASU 2023-07 during the fourth quarter of 2025. See Operating Segments Note.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 is intended to improve income tax disclosure requirements by requiring specific disclosure in the rate reconciliation and additional infor mation for reconciling items that meet a quantitative threshold. The guidance in ASU 2023-09 will be effective for annual reporting periods in fiscal years beginning after December 15, 2024. The Company will adopt the standard in its Annual Report on Form 10-K for the year ending October 31, 2026. The Company is currently evaluating the impact of the adoption of ASU 2023-09 and expects the adoption of the standard will only impact its disclosures with no material impact on its consolidated financial statements.
In November 2024, the FASB issued ASU 2024-03, Income Statement (Topic 220): Reporting Comprehensive Income. ASU 2024-03 does not change or remove current expense presentation requirements within the Consolidated Statements of Income. However, the amendments require disclosure, on an annual and interim basis, of disaggregated information about certain income statement expense line items within the notes to the consolidated financial statements. The amendments in this update are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures and anticipates adoption in fiscal 2028.
In September 2025, the FASB issued ASU 2025-06, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40) Targeted Improvements to the Accounting for Internal-Use Software (ASU 2025-06). This accounting standard changes when software project costs should be capitalized by removing all references to development stages and requiring costs to be capitalized when (1) the Company authorizes and commits to funding the software project and (2) it is probable the software project will be completed. The standard also requires additional annual and interim disclosures, including the capitalized software balance and accumulated amortization. ASU 2025-06 is effective for annual reporting periods, including interim reporting periods within those annual periods, beginning after December 15, 2027, with early adoption permitted and may be applied prospectively, retrospectively, or using a modified prospective transition approach. The Company is evaluating the impact of ASU 2025-06 to its consolidated financial statements and related disclosures.
Acquisitions
Business acquisitions have been accounted for using the acquisition method, with the acquired assets and liabilities recorded at estimated fair value on the dates of acquisition. The cost in excess of the net assets of the business acquired is included in goodwill. Operating results since the respective dates of acquisitions are included in the Condensed Consolidated Statements of Income.
Receivables
Our primary allowance for credit losses is the allowance for doubtful accounts, which is principally determined based on aging of receivables. Receivables are exposed to credit risk based on the customers' ability to pay which is influenced by, among other factors, their financial liquidity. We perform ongoing customer credit evaluation to maintain sufficient allowances for potential credit losses. Our segments perform credit evaluation and monitoring to estimate and manage credit risk through the review of customer information, credit ratings, approval and monitoring of customer credit limits and assessment of market conditions. We may also require prepayments or bank guarantees from customers to mitigate credit risk. Our receivables are generally short-term in nature with a majority of receivables outstanding less than 90 days. Accounts receivable balances are written-off against the allowance if deemed uncollectible.
Accounts receivable are net of an allowance for credit losses of $5,995 and $7,408 on April 30, 2026 and October 31, 2025, respectively. Provision for losses on receivables was $479 for the three months ended April 30, 2026, while provision for income on receivables was $110 for the six months ended April 30, 2026, compared to provision for income on receivables of $262 and $644 for the same periods last year, respectively. The remaining change in the allowance for credit losses is principally related to the write-off of uncollectible accounts.
Inventories
Components of inventories were as follows:
| April 30, 2026 | October 31, 2025 | |
|---|---|---|
| Finished goods | $255,559 | $234,710 |
| Raw materials and component parts | 236,254 | 230,907 |
| Work-in-process | 62,733 | 57,306 |
| 554,546 | 522,923 | |
| Obsolescence and other reserves | (86,789) | (78,109) |
| $467,757 | $444,814 |
Property, Plant and Equipment
Components of property, plant and equipment were as follows:
| April 30, 2026 | October 31, 2025 | |
|---|---|---|
| Land | $39,247 | $32,579 |
| Land improvements | 4,935 | 4,914 |
| Buildings | 364,726 | 360,038 |
| Machinery and equipment | 691,712 | 682,093 |
| Enterprise management system | 53,710 | 53,694 |
| Construction-in-progress | 37,111 | 29,522 |
| Leased property under finance leases | 32,760 | 27,680 |
| 1,224,201 | 1,190,520 | |
| Accumulated depreciation | (702,811) | (673,606) |
| $521,390 | $516,914 |
Depreciation expense was $16,909 and $17,881 for the three months ended April 30, 2026 and 2025, respectively. Depreciation expense was $33,925 and $35,601 for the six months ended April 30, 2026 and 2025, respectively.
Goodwill and other intangible assets
Our reporting units are the same as our reportable operating segments, Industrial Precision Solutions ("IPS"), Medical and Fluid Solutions ("MFS"), and the Advanced Technology Solutions ("ATS") segments. Changes in the carrying amount of goodwill for the six months ended April 30, 2026 by operating segment:
| IPS | MFS | ATS | Total | |
|---|---|---|---|---|
| Balance at October 31, 2025 | $1,210,366 | $1,647,468 | $446,851 | $3,304,685 |
| Currency effect | 24,888 | 720 | 2,634 | 28,242 |
| Balance at April 30, 2026 | $1,235,254 | $1,648,188 | $449,485 | $3,332,927 |
Information regarding intangible assets subject to amortization:
| Carrying Amount | AccumulatedAmortization | Net Book Value | |
|---|---|---|---|
| Customer relationships | $908,882 | $416,155 | $492,727 |
| Patent/technology costs | 236,872 | 166,438 | 70,434 |
| Trade name | 169,988 | 82,164 | 87,824 |
| Non-compete agreements | 8,657 | 8,657 | — |
| Other | 920 | 920 | — |
| Total | $1,325,319 | $674,334 | $650,985 |
| Carrying Amount | AccumulatedAmortization | Net Book Value | |
| Customer relationships | $899,402 | $390,751 | $508,651 |
| Patent/technology costs | 235,255 | 155,865 | 79,390 |
| Trade name | 169,127 | 75,581 | 93,546 |
| Non-compete agreements | 8,596 | 8,596 | — |
| Other | 929 | 929 | — |
| Total | $1,313,309 | $631,722 | $681,587 |
Amortization expense for the three months ended April 30, 2026 and 2025 was $19,406 and $19,697, respectively. Amortization expense for the six months ended April 30, 2026 and 2025 was $38,975 and $39,007, respectively.
Pension and other postretirement plans
During the second quarter of 2026, we completed a partial plan settlement transaction in regards to our U.S. pension plan in which plan assets amounting to $104,148 were used to purchase a group annuity contract from RGA Life and Annuity Insurance Company ("RGA"). The settlement resulted in a loss of $24,049 as shown on the Condensed Consolidated Statements of Income. This transaction relieved the Company of its responsibility for the pension obligation related to certain retired employees and transferred the obligation and payment responsibility to RGA for retirement benefits owed to approximately 1,000 retirees and other beneficiaries. The annuity contract covers retirees who commenced receiving benefits on or before February 1, 2026. The monthly retirement benefit payment amounts currently received by retirees and their beneficiaries did not change as a result of this transaction. Plan participants not included in the transaction remain in the plans and responsibility for payment of the retirement benefits remains with the Company.
The components of net periodic pension costs for the three and six months ended April 30, 2026 and 2025 were:
| U.S. | International | |||
|---|---|---|---|---|
| Three Months Ended | 2026 | 2025 | 2026 | 2025 |
| Service cost | $1,985 | $2,531 | $133 | $239 |
| Interest cost | 4,177 | 4,691 | 607 | 639 |
| Expected return on plan assets | (6,020) | (6,609) | (551) | (651) |
| Amortization of prior service credit | — | — | (2) | (2) |
| Amortization of net actuarial (gain) loss | 814 | 474 | (87) | (68) |
| Settlement loss | 24,049 | — | — | — |
| Total benefit cost | $25,005 | $1,087 | $100 | $157 |
| U.S. · International | ||||
| Six Months Ended | 2026 | 2025 | 2026 | 2025 |
| Service cost | $4,046 | $5,062 | $265 | $471 |
| Interest cost | 8,757 | 9,383 | 1,211 | 1,262 |
| Expected return on plan assets | (12,664) | (13,219) | (1,098) | (1,289) |
| Amortization of prior service credit | — | — | (4) | (4) |
| Amortization of net actuarial (gain) loss | 1,865 | 947 | (172) | (136) |
| Settlement loss | 24,049 | — | — | — |
| Total benefit cost | $26,053 | $2,173 | $202 | $304 |
The components of other postretirement benefit costs, for plans in the United States, for the three and six months ended April 30, 2026 and 2025:
| Three Months Ended | 2026 | 2025 |
|---|---|---|
| Service cost | $35 | $58 |
| Interest cost | 522 | 643 |
| Amortization of net actuarial gain | (413) | (124) |
| Total benefit cost | $144 | $577 |
| Six Months Ended | 2026 | 2025 |
| Service cost | $70 | $117 |
| Interest cost | 1,045 | 1,294 |
| Amortization of net actuarial gain | (827) | (250) |
| Total benefit cost | $288 | $1,161 |
The components of net periodic pension and other postretirement cost, other than service cost, are included in Other income (expense) – net and Pension settlement charge in our Condensed Consolidated Statements of Income.
Income taxes
We record our interim provision for income taxes based on our estimated annual effective tax rate, as well as certain items discrete to the current period. The effective tax rate for the three months ended April 30, 2026 and 2025 was 16.9% and 19.0%, respectively. The effective tax rate for the six months ended April 30, 2026 and 2025 was 18.0% and 19.0%, respectively. The effective tax rate for the three and six months ended April 30, 2026 was lower than the U.S. tax rate of 21% primarily due to the foreign-derived intangible income deduction.
The Company continues to assess the impact of the One Big Beautiful Bill Act ("OBBBA"), enacted on July 4, 2025 and taking effect during the Company’s fiscal year ending October 31, 2026. There is no material impact from OBBBA on the effective tax rate or consolidated financial statements for the quarter ended April 30, 2026.
Accumulated other comprehensive income (loss)
Changes in accumulated other comprehensive income (AOCI) consisted of:
| Cumulativetranslation and related hedging instruments | Pension andpostretirement benefit planadjustments | Accumulatedother comprehensiveincome (loss) | |
|---|---|---|---|
| Balance at October 31, 2025 (1) | $(50,518) | $(49,939) | $(100,457) |
| Other comprehensive income before reclassification adjustments | 41,400 | 13,360 | 54,760 |
| Reclassifications from AOCI to Statement of Income (2) | — | 24,891 | 24,891 |
| Tax impact | 4,024 | (8,810) | (4,786) |
| Balance at April 30, 2026 (1) | $(5,094) | $(20,498) | $(25,592) |
(1)Amounts net of tax.
(2)Included in the computation of net periodic cost (benefit) which is included in Other income (expense) - net in our Consolidated Statements of Income. See Pension and other postretirement plans Note.
Warranties
We offer warranties to our customers depending on the specific product and terms of the customer purchase agreement. A typical warranty program requires that we repair or replace defective products within a specified time period (generallyone year) measured from the date of delivery or first use. We record an estimate for future warranty-related costs based on actual historical return rates. Based on analysis of return rates and other factors, the adequacy of our warranty provisions is adjusted as necessary. The liability for warranty costs is included in Accrued liabilities in the Consolidated Balance Sheets.
Following is a reconciliation of the product warranty liability for the six months ended April 30, 2026 and 2025:
| 2026 | 2025 | |
|---|---|---|
| Beginning balance at October 31 | $13,900 | $13,538 |
| Accruals for warranties | 5,737 | 4,719 |
| Warranty payments | (5,067) | (5,536) |
| Currency adjustments | (343) | 64 |
| Ending balance | $14,227 | $12,785 |
Operating segments
We conduct business in three primary operating segments:
Industrial Precision Solutions: This segment focuses on delivering proprietary dispensing and processing technology, both standard and highly customized equipment, to diverse end markets. Product lines commonly reduce material consumption, increase line efficiency through precision dispensing and enhance product brand and appearance. Components are used for dispensing adhesives, coatings, paint, finishes, sealants and other materials. This segment primarily serves the industrial, agricultural, consumer durables and non-durables markets.
Medical and Fluid Solutions: This segment includes the Company’s fluid management solutions for medical, high-tech industrial and other diverse end markets. Related plastic tubing, balloons, catheters, syringes, cartridges, tips and fluid connection components are used to dispense or control fluids within customers’ medical devices or products, as well as production processes.
Advanced Technology Solutions: This segment focuses on products serving electronics and consumer non-durable end markets. Advanced Technology Solutions products integrate our proprietary product technologies found in progressive stages of an electronics customer’s production and measurement and control processes, such as surface treatment, precisely controlled dispensing of material and test and inspection to ensure quality and reliability. Applications include, but are not limited to, semiconductors, printed circuit boards, electronic components and automotive electronics, in-line measurement sensors, gauges and analyzers.
The composition of segments and measure of segment profitability is consistent with that used by our chief operating decision maker ("CODM"), our President and Chief Executive Officer. The primary measure used by our CODM for purposes of making decisions about allocating resources to the segments and assessing performance is segment EBITDA, which equals sales less adjusted cost of sales and adjusted selling and administrative expenses plus depreciation. Cost of sales and selling and administrative expenses are adjusted for certain special items such as non-recurring cost reduction activities and acquisition related costs, including intangible asset amortization. The CODM uses segment EBITDA in the annual budgeting and forecasting processes and regularly evaluates segment EBITDA results versus budget, forecast and prior year when making allocation of capital, financial and employee resource decisions.
The accounting policies of the segments are the same as those described in our Significant accounting policies Note. There are no intersegment sales. Certain expenses are maintained at the corporate level and not allocated to the segments. These expenses include executive compensation, charitable donations, corporate facilities, and other items that are of a corporate or functional governance nature. Interest expense-net and Other income (expense) - net are excluded from the measure of segment profitability reviewed by our CODM and are not presented by operating segment.
The following table presents information about our reportable segments as further reconciled to consolidated GAAP financial results:
| Three Months Ended | Six Months Ended | |||
|---|---|---|---|---|
| April 30, 2026 | April 30, 2025 | April 30, 2026 | April 30, 2025 | |
| Sales | ||||
| Industrial Precision Solutions | $350,466 | $318,847 | $677,327 | $619,295 |
| Medical and Fluid Solutions | 212,850 | 202,809 | 406,033 | 396,418 |
| Advanced Technology Solutions | 177,531 | 161,282 | 326,948 | 282,645 |
| Total segment sales | 740,847 | 682,938 | 1,410,308 | 1,298,358 |
| Adjusted cost of sales | ||||
| Industrial Precision Solutions | (142,315) | (127,720) | (277,070) | (240,867) |
| Medical and Fluid Solutions | (108,167) | (101,362) | (204,722) | (204,731) |
| Advanced Technology Solutions | (85,153) | (76,456) | (157,182) | (131,315) |
| Total segment adjusted cost of sales | (335,635) | (305,538) | (638,974) | (576,913) |
| Adjusted selling and administrative expenses | ||||
| Industrial Precision Solutions | (90,580) | (83,174) | (178,330) | (163,343) |
| Medical and Fluid Solutions | (33,323) | (33,581) | (67,585) | (68,193) |
| Advanced Technology Solutions | (45,551) | (46,997) | (91,926) | (92,314) |
| Total segment adjusted selling and administrative expenses | (169,454) | (163,752) | (337,841) | (323,850) |
| Depreciation | ||||
| Industrial Precision Solutions | 6,007 | 5,595 | 11,962 | 11,239 |
| Medical and Fluid Solutions | 7,833 | 8,672 | 15,673 | 17,376 |
| Advanced Technology Solutions | 1,500 | 1,687 | 3,087 | 3,271 |
| Total segment depreciation | 15,340 | 15,954 | 30,722 | 31,886 |
| EBITDA | ||||
| Industrial Precision Solutions | 123,578 | 113,548 | 233,889 | 226,324 |
| Medical and Fluid Solutions | 79,193 | 76,538 | 149,399 | 140,870 |
| Advanced Technology Solutions | 48,327 | 39,516 | 80,927 | 62,287 |
| Total segment EBITDA | 251,098 | 229,602 | 464,215 | 429,481 |
| Inventory step-up amortization | (1,135) | — | (1,135) | (3,135) |
| Acquisition related costs | (534) | (513) | (534) | (1,543) |
| Severance and other | — | (10,313) | — | (16,274) |
| Depreciation and amortization | (36,315) | (37,578) | (72,900) | (74,608) |
| Corporate expenses | (15,911) | (12,448) | (26,038) | (24,224) |
| Interest expense | (21,942) | (26,572) | (45,073) | (53,131) |
| Interest and investment income | 362 | 553 | 752 | 1,494 |
| Pension settlement charge | (24,049) | — | (24,049) | — |
| Other - net | (10,400) | (3,961) | 10,437 | (2,435) |
| Income before taxes | $141,174 | $138,770 | $305,675 | $255,625 |
The following table presents additional information about our reportable segments:
| Industrial Precision Solutions | Medical and Fluid Solutions | Advanced Technology Solutions | Corporate | Total | |
|---|---|---|---|---|---|
| Amortization of intangibles | $7,552 | $9,533 | $2,321 | $— | $19,406 |
| Property, plant and equipment expenditures | 2,467 | 5,479 | 2,234 | — | 10,180 |
| Amortization of intangibles | $7,019 | $9,695 | $2,983 | $— | $19,697 |
| Property, plant and equipment expenditures | 4,054 | 2,269 | 7,851 | 1,865 | 16,039 |
| Amortization of intangibles | 15,072 | 19,204 | 4,699 | — | 38,975 |
| Property, plant and equipment expenditures | 5,732 | 10,804 | 11,002 | 155 | 27,693 |
| Amortization of intangibles | 13,828 | 19,132 | 6,047 | — | 39,007 |
| Property, plant and equipment expenditures | 13,583 | 17,181 | 4,393 | 2,282 | 37,439 |
| Identifiable assets (1) | 1,898,264 | 2,191,580 | 772,837 | 1,101,737 | 5,964,418 |
| Identifiable assets (1) | 1,858,974 | 2,201,528 | 738,762 | 1,118,417 | 5,917,681 |
(1) Operating segment identifiable assets include notes and accounts receivable net of allowance for doubtful accounts, inventories net of reserves, property, plant and equipment net of accumulated depreciation and goodwill. Corporate assets are principally cash and cash equivalents, deferred income taxes, leases, headquarter facilities and intangible assets.
We had significant net sales, measured based on their geographic destination, as follows:
| Three Months Ended | Six Months Ended | |||
|---|---|---|---|---|
| April 30, 2026 | April 30, 2025 | April 30, 2026 | April 30, 2025 | |
| Net external sales | ||||
| Americas | $308,253 | $292,463 | $570,183 | $560,300 |
| Europe | 194,459 | 172,496 | 376,920 | 340,259 |
| Asia Pacific | 238,135 | 217,979 | 463,205 | 397,799 |
| Total net external sales | 740,847 | 682,938 | 1,410,308 | 1,298,358 |
Investments
The Company holds minority interests in certain companies that do not have readily determinable fair values. For each qualifying investment, the Company elects the measurement alternative under ASC 321, initially recognizing the investment at cost and subsequently adjusting the carrying amount for (i) impairment and (ii) observable price changes in orderly transactions for an identical or similar investment of the same issuer. Investments subject to the measurement alternative are classified in Other assets on the Consolidated Balance Sheets and were $5,040 and $13,996, at April 30, 2026 and October 31, 2025, respectively. Adjustments (upward or downward) and impairment losses, if any, are recognized in earnings within Other income (expense) - net and were not material for the three and six months ended April 30, 2026 and 2025. If a readily determinable fair value for the investments subsequently becomes available, we will be required to record the investment at fair value with any unrealized gains or losses being recognized in earnings each period.
In December 2025, one of the Company's minority interest investments was publicly listed on a foreign stock exchange. The fair value of this investment is included in Other assets on the Consolidated Balance Sheets and was $21,722 as of April 30, 2026. The unrealized loss of $9,827 for the three months ended April 30, 2026 and unrealized gain of $12,411 for the six months ended
April 30, 2026 was included in Other income (expense) - net in the Condensed Consolidated Statements of Income. Nordson is contractually restricted from selling any shares in this investment until December 2028, and there are no circumstances that could cause this restriction to lapse earlier.
Fair value measurements
The inputs to the valuation techniques used to measure fair value are classified into the following categories:
Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs that are not corroborated by market data.
The following tables present the classification of our assets and liabilities measured at fair value on a recurring basis:
| April 30, 2026 | Total | Level 1 | Level 2 | Level 3 |
|---|---|---|---|---|
| Net derivative contracts (1) | $(64,923) | $— | $(64,923) | $— |
| Deferred compensation plans (2) | (13,873) | — | (13,873) | — |
| Minority interest investment (3) | 21,722 | 21,722 | — | — |
| October 31, 2025 | Total | Level 1 | Level 2 | Level 3 |
|---|---|---|---|---|
| Net derivative contracts (1) | $(55,367) | $— | $(55,367) | $— |
| Deferred compensation plans (2) | (11,885) | — | (11,885) | — |
(1) Derivative contracts are valued using an industry standard market approach, in which prices and other relevant information is generated by market transactions involving identical or comparable assets or liabilities. Refer to Derivative financial instruments note for balance sheet classification of derivatives.
(2) Executive officers and other highly compensated employees may defer up to 100% of their salary and annual cash incentive compensation and for executive officers, up to 90% of their long-term incentive compensation, into various non-qualified deferred compensation plans. Deferrals can be allocated to various market performance measurement funds. Changes in the value of compensation deferred under these plans are recognized each period based on the fair value of the underlying measurement funds.
(3) Refer to Investments note for additional details.
The carrying amounts and fair values of financial instruments, other than cash and cash equivalents, receivables and accounts payable are shown in the table below. The carrying values of cash and cash equivalents, receivables and accounts payable approximate fair value due to the short-term nature of these instruments.
| April 30, 2026 | October 31, 2025 | |||
|---|---|---|---|---|
| Carrying Amount | Fair Value | Carrying Amount | Fair Value | |
| Long-term debt (including current portion) | $1,879,952 | $1,910,744 | $1,996,254 | $2,038,869 |
Long-term debt is valued by discounting future cash flows at currently available rates for borrowing arrangements with similar terms and conditions, which are considered to be Level 2 inputs under the fair value hierarchy. The carrying amount of long-term debt is shown net of unamortized debt issuance costs and bond discounts as described in the Long-term debt Note.
Derivative financial instruments
The Company uses derivative instruments to manage foreign currency and interest rate risk as detailed below. The Company does not enter into derivative instruments for trading purposes.
Foreign Currency Forward Contracts
We operate internationally and enter into transactions denominated in foreign currencies. Consequently, we are subject to market risk arising from exchange rate movements between the dates foreign currency transactions occur and the dates they are settled. We regularly use foreign currency forward contracts to reduce our risks related to most of these transactions. These contracts usually have maturities of 90 days or less and generally require us to exchange foreign currencies for U.S. dollars at maturity, at rates stated in the contracts. These contracts are not designated as hedging instruments under U.S. GAAP. The settlement of these contracts is recorded in operating activities on the Consolidated Statement of Cash Flows.
We are exposed to credit-related losses in the event of nonperformance by counterparties to financial instruments. These financial instruments include cash deposits and foreign currency forward contracts. We periodically monitor the credit ratings of these counterparties in order to minimize our exposure. Our customers represent a wide variety of industries and geographic regions. As of April 30, 2026 and 2025, there were no significant concentrations of credit risk.
Net Investment Hedges
Net assets of our foreign subsidiaries are exposed to volatility in foreign currency exchange rates. We may utilize net investment hedges to offset the translation adjustment arising from re-measuring our investment in foreign subsidiaries.
The Company is a party to various cross currency swaps between the U.S. dollar and Euro, Japanese Yen, Taiwan dollar, Singapore dollar and Chinese Yuan, which were designated as hedges of our net investments in certain foreign subsidiaries to mitigate the foreign exchange risk associated with certain investments in these subsidiaries. Any increases or decreases related to the remeasurement of the effective portion of the hedges are recorded in the currency translation component of Accumulated other comprehensive income (loss) within Shareholders' Equity in the Consolidated Balance Sheets until the sale or substantial liquidation of the underlying investments. The settlement of these hedges is recorded in investing activities on the Consolidated Statement of Cash Flows. The interest component is recorded in operating activities on the Consolidated Statement of Cash Flows.
Fair Value Hedges of Interest Rate Risk
The Company is exposed to changes in the fair value of certain of its fixed-rate liabilities due to changes in benchmark interest rates. The Company uses interest rate swaps to manage its exposure to changes in fair value on these instruments attributable to changes in the designated benchmark interest rate, the Secured Overnight Financing Rate ("SOFR"), with the objective of minimizing the cost of borrowed funds. The Company's interest rate swaps involve the receipt of fixed-rate amounts from a counterparty in exchange for the Company making variable-rate payments without the exchange of the underlying notional amount.
The Company's interest rate swaps are designated and qualify as fair value hedges. As a result, the interest rate swaps are measured at fair value and the carrying value of the hedged debt is adjusted for the change in value related to the exposure being hedged, with both adjustments offset to earnings. Accordingly, the earnings effect of an increase in the fair value of the interest rate swaps will be substantially offset by the earnings effect of the increase in the carrying value of the hedged debt.
The following table provides information regarding the Company's outstanding interest rate derivatives that were used to hedge changes in fair value attributable to interest rate risk:
| Interest rate swaps - notional amount | Cumulative adjustment to long-term debt from application of hedge accounting | Carrying value of hedged debt | |
|---|---|---|---|
| Interest rate swaps | $300,000 | $6,404 | $306,404 |
The following table provides information regarding the balance sheet and income statement impacts of the Company's derivatives:
| April 30, 2026 · Notional Amount $ · Prepaid and other current assets · Other assets · Accrued liabilities · Other long-term liabilities · Type of hedge | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Derivatives designated as hedges: | ||||||||||
| Cross-currency swap | $920,584 | $6,461 | $— | $9,190 | $69,131 | Net investment | ||||
| Interest rate swap | 300,000 | 1,122 | 5,282 | — | — | Fair value | ||||
| Derivatives not designated as hedges: | ||||||||||
| Foreign currency forward contracts | 1,049,730 | 5,583 | — | 5,050 | — | |||||
| Total | $13,166 | $5,282 | $14,240 | $69,131 | ||||||
| October 31, 2025 · Notional Amount $ · Prepaid and other current assets · Other assets · Accrued liabilities · Other long-term liabilities · Type of hedge | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Derivatives designated as hedges: | ||||||||||
| Cross-currency swap | $863,904 | $5,937 | $— | $676 | $61,725 | Net investment | ||||
| Interest rate swap | 300,000 | 1,133 | 10,353 | — | — | Fair value | ||||
| Derivatives not designated as hedges: | ||||||||||
| Foreign currency forward contracts | 1,137,956 | 4,961 | — | 15,350 | — | |||||
| Total | $12,031 | $10,353 | $16,026 | $61,725 | ||||||
| Gain (Loss) Recognized · Gain (Loss) Recognized · Location | |||||
|---|---|---|---|---|---|
| Three Months Ended · Six Months Ended | |||||
| April 30, 2026 · April 30, 2025 · April 30, 2026 · April 30, 2025 | |||||
| Derivatives designated as hedges: | |||||
| Interest rate swaps | $(3,007) | $9,581 | $(5,362) | $12,567 | Interest expense |
| Hedged item | $3,007 | $(9,581) | $5,362 | $(12,567) | Interest expense |
| Cross-currency swap - interest component | $4,699 | $3,541 | $8,327 | $7,278 | Interest expense |
| Cross-currency swap - effective portion | $9,392 | $(63,794) | $(17,168) | $(26,756) | Cumulative translation |
| Derivatives not designated as hedges | |||||
| Foreign currency forward contracts | $(12,657) | $22,314 | $10,922 | $17,951 | Other income (expense) - net |
| Foreign currency balance sheet remeasurement | $10,272 | $(25,513) | $(15,601) | $(20,819) | Other income (expense) - net |
Long-term debt
A summary of long-term debt is as follows:
| April 30, 2026 | October 31, 2025 | |
|---|---|---|
| Revolving credit agreement, due 2031 | 295,000 | — |
| Revolving credit agreement, due 2028 | — | 135,000 |
| Term loan due 2026 | — | 265,000 |
| Senior notes, due 2026-2027 | 20,000 | 20,000 |
| Senior notes, due 2026-2030 | 130,000 | 130,000 |
| 5.600% Notes due 2028 | 350,000 | 350,000 |
| 5.800% Notes due 2033 | 500,000 | 500,000 |
| 4.500% Notes due 2029 | 600,000 | 600,000 |
| 1,895,000 | 2,000,000 | |
| Less current maturities | 50,000 | 315,000 |
| Less unamortized debt issuance costs | 13,172 | 13,167 |
| Less bond discounts | 1,876 | 2,065 |
| Plus impact of interest rate swaps | 6,404 | 11,486 |
| Long-term maturities | $1,836,356 | $1,681,254 |
Revolving credit agreement— In January 2026, we entered into a $1,200,000 senior unsecured multicurrency revolving credit facility with a group of banks, maturing in January 2031 (the “Revolving Credit Agreement”), which amended and restated the Company’s previous unsecured senior credit agreement, dated June 6, 2023, that included a term loan facility in the aggregate principal amount of $300,000, maturing in June 2026, and a multicurrency revolving credit facility in the aggregate principal amount of $922,500, maturing in June 2028. The Company borrowed and had $295,000 outstanding under the Revolving Credit Agreement as of April 30, 2026. The Revolving Credit Agreement permits borrowing in U.S. Dollars, Euros, Sterling, Swiss Francs, Singapore Dollars, Japanese Yen, and each other currency approved by the Revolving Agent and the Revolving Credit Banks (each as defined in the Revolving Credit Agreement). Loans under the Revolving Credit Agreement bear interest at the sum of (i) either a base rate or, depending on the currency, a SOFR rate, EURIBOR rate, TIBOR rate, SORA rate, SONIA rate or SARON rate (each as defined in the Revolving Credit Agreement) plus (ii) an applicable margin. The applicable margin is based on either the Company’s Leverage Ratio (as defined in the Revolving Credit Agreement) or then current Debt Rating (as defined in the Revolving Credit Agreement). The weighted-average interest rate at April 30, 2026 was 4.69%.
Senior notes, due 2026-2027— These unsecured fixed-rate notes entered into in 2015 with a group of insurance companies have a remaining weighted-average life of 0.74 years. The weighted-average interest rate at April 30, 2026 was 3.19%.
Senior notes, due 2026-2030— These unsecured fixed-rate notes entered into in 2018 with a group of insurance companies have a remaining weighted-average life of 2.15 years. The weighted-average interest rate at April 30, 2026 was 4.08%.
5.600% Notes due 2028 and 5.800% Notes due 2033— In September 2023, we completed an underwritten public offering of $350,000 aggregate principal amount of 5.60% Notes due 2028 and $500,000 aggregate principal amount of 5.80% Notes due 2033.
4.500% Notes due 2029— In September 2024, we completed an underwritten public offering of $600,000 aggregate principal amount of 4.50% Notes due 2029.
We were in compliance with all covenants at April 30, 2026, and the amount we could borrow would not have been limited by any debt covenants.
Contingencies
We are involved in pending or potential litigation regarding environmental, product liability, patent, contract, employee and other matters arising from the normal course of business. After consultation with legal counsel, we do not believe that losses in excess of the amounts we have accrued would have a material adverse effect on our financial condition, quarterly or annual operating results or cash flows.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.